Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Renal Impairment Clinical Trial

Official title:

Evaluation of the Pharmacokinetics and Safety of Venetoclax in Subjects With Impaired Renal Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04810598
• Other study ID #: M19-065
• Status: Completed
• Phase: Phase 1
• Start date: July 8, 2021
• Est. completion date: August 16, 2022

Study information

• Verified date: September 2022
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female participants with severe normal renal function and those with end stage renal disease (ESRD) requiring hemodialysis. Venetoclax is an investigational drug being developed for the treatment of various hematologic malignancies. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Approximately 12 female participants between 18 and 75 years, with Body Mass Index (BMI) between 18 to 42 kg/m2 will be enrolled in approximately 4 sites across the world. Participants with normal renal function will receive single dose of oral venetoclax tablet. Participants with ESRD will receive oral venetoclax tablets just prior to hemodialysis (Period 1 Day 1) and between dialysis days (Period 2 Day 1), doses in the two periods will be separated by at least 7 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood and urine tests, checking for side effects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: August 16, 2022
• Est. primary completion date: August 16, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Body mass index (BMI) between 18.0 and 42.0 kg/m2.
• Postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
• Women of childbearing potential, practicing at least 2 protocol specified methods of birth control that are effective from at least 30 days before starting study drug through at least 30 days after the last dose of any study drug.
• Group 1 only: Must be in general good health based upon the results of a medical history, physical examination, and 12-lead electrocardiogram (ECG) with normal Glomerular Filtration Rate (GFR) at Screening.
• Group 2 only: Stable condition and acceptable for study participation based upon the results of a medical history, physical examination, laboratory profile, and ECG. Participant with end stage renal disease (ESRD) requiring dialysis on hemodialysis must have been receiving hemodialysis for at least 1 month.

Exclusion Criteria:

• Participants on a strict vegetarian or vegan diet.

Related Conditions & MeSH terms

• Kidney Diseases
• Renal Disease
• Renal Impairment
• Renal Insufficiency

Intervention

Drug:
• Venetoclax
Oral Tablet

Locations

Country	Name	City	State
United States	Acpru /Id# 243398	Grayslake	Illinois
United States	Orlando Clinical Research Ctr /ID# 224922	Orlando	Florida

Sponsors (2)

Lead Sponsor	Collaborator
AbbVie	Roche-Genentech

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With Adverse Events (AEs)	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.	Up to approximately 38 days
Primary	Maximum Plasma Concentration (Cmax) of Venetoclax (Groups 1,2)	Maximum Plasma Concentration (Cmax) of Venetoclax.	Up to Day 6
Primary	Time to Cmax (Tmax) of Venetoclax (Groups 1,2)	Time to Cmax (Tmax) of Venetoclax.	Up to Day 6
Primary	Area Under the Plasma Concentration-time Curve over time from time 0 to 48 hours (AUC0-48) of Venetoclax (Groups 1,2)	Area Under the Plasma Concentration-time Curve over time from time 0 to 48 hours (AUC0-48).	Up to Day 6
Primary	Pre-dose Unbound Fraction (fu) of Venetoclax in Plasma (Groups 1,2)	Unbound Fraction (fu) of Venetoclax in Plasma.	Day 1
Primary	Dialysis Clearance (CLdialysis) (Group 2)	Dialysis Clearance (CLdialysis) is calculated in participants undergoing hemodialysis in Period 1.	Day 1
Primary	Unbound Fraction Pre-dialysis (fu,predialysis) of Venetoclax in Plasma (Group 2)	Unbound fraction pre-dialysis (fu,predialysis) of venetoclax in plasma is calculated in participants undergoing hemodialysis in Period 1.	Day 1
Primary	Unbound Fraction Post-dialysis (fu,postdialysis) of Venetoclax in Plasma (Group 2)	Unbound fraction post-dialysis (fu,postdialysis) of venetoclax in plasma is calculated in participants undergoing hemodialysis in Period 1.	Day 1

External Links

•   This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.